This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan A. McNab, FRACO; Penny McKelvie, FRCPA

Arch Ophthalmol. 1997;115(7):919-921.

Abstract
Well-recognized risk factors for zygomycosis include diabetic ketoacidosis, immunocompromise, and deferoxamine therapy for iron or aluminum overload, usually in patients undergoing kidney dialysis. We report a case of fatal nasal-orbital-cerebral zygomycosis in an 82-year-old man with known myelodysplasia and well-controlled diabetes. He was not receiving deferoxamine. Despite radical surgery and amphotericin B therapy, he died; primary hemochromatosis with gross iron overload was found post mortem. Experimental evidence suggests iron overload without deferoxamine therapy may be a risk factor for zygomycosis; the findings in this case would support this hypothesis.

Author Affiliations
From the Royal Victorian Eye and Ear Hospital (Dr McNab) and the Department of Anatomical Pathology, St Vincent's Hospital, Fitzroy (Dr McKelvie), Melbourne, Australia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rhizomycosis Infection in the Basal Ganglia
Pandian et al.
Arch Neurol 2007;64:134-135.
FULL TEXT  

Zygomycetes in Human Disease
Ribes et al.
Clin. Microbiol. Rev. 2000;13:236-301.
ABSTRACT | FULL TEXT